French Biotech Allogenica Secures €2.5M Grant to Advance Universal CAR-T Therapy Industrialization

Allogenica, a biotechnology company based in Lyon, has secured €2.5 million in funding from the French government’s France 2030 strategic investment program. The grant will accelerate the industrial development of the company’s universal (off-the-shelf) CAR-T therapy platform, designed for applications in hematologic cancers, rare diseases, and autoimmune disorders.

Universal CAR-T therapies, unlike autologous approaches, are manufactured in advance and stored for immediate use, removing the need for patient-specific cell collection. This model promises faster treatment access, lower costs, and improved scalability. The newly awarded funds will support Allogenica’s efforts to expand GMP manufacturing capacity, enhance gene-editing workflows, and advance clinical readiness.

Industry Significance

This funding marks another step in Europe’s growing commitment to biotherapy independence and next-generation manufacturing. Universal CAR-T therapy represents one of the most transformative directions in cell therapy, offering the potential to reduce production complexity and broaden clinical accessibility. As companies like Allogenica push forward, the ecosystem of advanced CDMO partners will play a vital role in translating these innovations into large-scale therapeutic reality.

Source: Reuters, Allogenica secures €2.5 million grant to advance universal CAR-T therapy, September 2025

About Hillgene

Hillgene is a biotechnology company specializing in cell and gene therapy CDMO services, providing end-to-end solutions from process development to GMP manufacturing. Leveraging expertise in viral vector production, stable cell line generation, and immune cell expansion, Hillgene empowers global partners to accelerate preclinical and clinical translation. → Click to Learn More 

Photo by Jonas Jacobsson on Unsplash